查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1992957

DNA疫苗市场：2026-2032年全球市场预测（依技术平台、递送方式、给药途径、研发阶段、应用及最终用户划分）

DNA Vaccine Market by Technology Platform, Delivery Method, Administration Route, Development Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

DNA疫苗市场预计到2025年价值为3.4445亿美元，到2026年增长至3.9386亿美元，到2032年达到8.6867亿美元，复合年增长率为14.12%。

主要市场统计数据
基准年 2025 3.4445亿美元
预计年份：2026年 3.9386亿美元
预测年份 2032 8.6867亿美元
复合年增长率 (%) 14.12%

引言概述了正在重塑全球 DNA 疫苗开发的新科学势头、递送技术创新和战略意义。

在核酸疗法和递送技术进步的推动下，DNA疫苗的科学和商业性发展正进入一个更严格检验和选择性开发的阶段。历史上，DNA疫苗因其理论优势（例如热稳定性、易于设计以及能够编码复杂抗原）而备受重视，但由于递送效率低和人体免疫抗原性不足，其广泛应用受到限制。然而，近年来质体工程、线性及微环DNA平台以及对先天免疫调控机制更深入理解方面的进展，重新激发了研发人员、资助者和临床研究人员的兴趣。

技术、临床策略和相关人员行为的变革性变化将加速DNA疫苗的实际应用和策略合作。

DNA疫苗领域经历了翻天覆地的变化，这主要归因于三个密切相关的因素：技术进步、临床检验趋势以及相关人员不断变化的期望。分子支架和载体设计的进步拓展了能够在体内可靠表达的抗原构建体的种类，而线性DNA和微环平台的出现则为研发人员在表达效率和生产便捷性之间提供了新的权衡方案。同时，电穿孔和脂质聚合物奈米颗粒等递送方法的改进显着降低了传统上有效活化免疫反应的障碍。

2025 年关税趋势和贸易政策调整的变化将如何影响供应链策略、采购重点和製造在地化方面的决策？

2025年关税调整和贸易政策调整的累积影响，进一步加剧了支持DNA疫苗研发和生产的全球供应链的复杂性。质体和线性DNA生产的关键原料——特殊酵素、层析法树脂、一次性生物製程组件和试剂级耗材——极易受到跨境成本波动的影响。随着关税增加投入成本和采购不确定性，疫苗研发机构和合约开发与生产组织（CDMO）正透过重新审视其筹资策略、扩大库存缓衝以及与本地供应商建立合作关係来应对，以稳定前置作业时间。

关键细分洞察揭示了应用重点、平台选择、剂量、临床阶段和最终用户趋势如何影响专案策略和商业化计划。

基于细分市场的洞察揭示了每种适应症、技术平台、给药方法、给药途径、研发阶段和最终用户的不同开发路径和商业性考虑。从适应症角度来看，针对感染疾病（感染疾病为细菌、寄生虫和病毒感染疾病）的项目往往强调快速诱导免疫、低温运输和可扩展性，而专注于骨髓恶性肿瘤和固体癌的肿瘤项目则优先考虑抗原特异性、联合免疫疗法策略和肿瘤微环境的调控。平台选择（线性DNA、微环DNA或质体DNA）会影响人们对生产复杂性、有效载荷能力和基因组安全性的认知，进而影响监管沟通和合作伙伴的选择。

提供可操作的区域性见解，解释美洲、欧洲、中东和非洲以及亚太地区在法规、製造业和医疗保健系统方面的差异如何影响专案策略。

鑑于法律规范、医疗基础设施和生产能力的差异，区域观点影响各个市场开发商和投资者的策略重点。在美洲，强大的资本市场和以创新为导向的法规环境有利于早期临床试验和官民合作关係，而集中的製造群支持快速规模化生产和垂直整合的供应链。相较之下，欧洲、中东和非洲（EMEA）的环境则较为复杂，监管协调的努力与不同的准入途径和采购机制并存，这要求申办方制定灵活的临床开发计划和与支付方的沟通策略，以适应当地的报销惯例。

从企业层面提供关键见解，解释平台开发商、临床阶段生物技术公司、主要製药合作伙伴和 CDMO 如何合作加速 DNA 疫苗的进展。

DNA疫苗领域的企业组成既有竞争又有合作，包括专业平台开发公司、临床阶段生物技术公司、大型製药合作伙伴以及契约製造组织（CDMO）。平台开发公司透过分子设计、专有递送佐剂或旨在降低生产成本和提高表达效率的生产流程创新来脱颖而出。临床阶段生物技术公司通常专注于特定适应症，并利用独特的免疫学特征和生物标记组合来加速概念验证（PoC）。而大型製药企业则倾向于寻求策略联盟和许可，以补充其现有的疫苗产品组合和分销能力。

为行业领导者提供实用建议，以优先考虑交付技术创新、供应链韧性、监管策略、合作伙伴关係和个人化商业化策略。

产业领导者可以采取一系列实际有效的措施来降低风险，同时加速研发和商业化进程。首先，优先投资于能够显着改善抗原表达和提高患者耐受性的递送技术和给药途径，并使这些投资与目标适应症的特性和最终用户的需求相匹配。其次，透过认证多家供应商、探索区域製造伙伴关係关係以及将关税和贸易应急计划纳入筹资策略，增强供应链韧性，以避免专案中断并确保按计划进行。

本研究调查方法阐述了支持这些发现的综合方法，包括综合文献分析、监管审查、专家访谈和供应链分析。

这项高阶主管级分析所依据的研究结合了对同侪审查文献、临床试验註册资讯、监管指导文件和公开技术报告的系统性回顾，以及有针对性的专家访谈。研究对科学和临床发现进行了交叉检验，以确保临床前检验、剂量表现和临床开发模式的一致性。透过分析近期关税表、官方贸易公告和供应链中断案例研究，评估了贸易和政策的影响，重点在于采购和生产决策如何即时调整。

综合考虑技术进步、营运要求和区域因素，这些因素共同决定了DNA疫苗产生影响的路径。

总之，DNA疫苗正从主要停留在理论层面，逐步成为现代免疫疗法和预防策略的实际应用要素。平台工程的进步，以及给药方法和实践的显着改进，正在扩大DNA疫苗的适应症范围，使其更具竞争力。同时，贸易政策趋势和区域环境的差异等外部因素，也要求在生产、采购和打入市场策略进行週详的规划。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依技术平台分類的DNA疫苗市场

  • 线性DNA
  • 迷你环状DNA
  • 质体DNA

第九章：DNA疫苗市场：依递送方式划分

  • 电穿孔
  • 基因枪
  • 奈米颗粒递送
  • 针头注射

第十章：DNA疫苗市场依给药途径分類的分布

  • 皮内注射
  • 肌肉内部
  • 鼻腔
  • 皮下

第十一章：DNA疫苗市场依研发阶段划分

  • I期临床试验
  • 二期临床试验
  • III期临床试验
  • 商业的
  • 临床前

第十二章：DNA疫苗市场：依应用领域划分

  • 感染疾病
    • 细菌感染疾病
    • 寄生虫病
    • 病毒感染疾病
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固体癌

第十三章：DNA疫苗市场：依最终用户划分

  • 诊所
  • 医院
  • 研究机构

第十四章 DNA疫苗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：DNA疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 DNA疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国DNA疫苗市场

第十八章：中国DNA疫苗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aura Health
  • Breethe
  • Buddhify
  • Calm
  • Chopra Center
  • Gaia
  • Glo
  • Headspace
  • Inner Explorer
  • Inscape
  • Insight Network
  • Inward
  • MEDITOPIA
  • Mindfulness Everywhere
  • MOBIO INTERACTIVE
  • Muse
  • Omvana
  • Pacifica
  • Sattva
  • Simple Habit
  • Smiling Mind
  • WAKING UP
Product Code: MRR-1A1A064C0154

The DNA Vaccine Market was valued at USD 344.45 million in 2025 and is projected to grow to USD 393.86 million in 2026, with a CAGR of 14.12%, reaching USD 868.67 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 344.45 million
Estimated Year [2026] USD 393.86 million
Forecast Year [2032] USD 868.67 million
CAGR (%) 14.12%

Introduction framing the renewed scientific momentum, delivery innovations, and strategic implications that are reshaping DNA vaccine development globally

The scientific and commercial narrative for DNA vaccines has entered a phase of intensified scrutiny and selective momentum, prompted by broader nucleic acid therapy progress and refined delivery science. Historically, DNA vaccines were celebrated for their theoretical advantages-thermostability, ease of design, and capacity to encode complex antigens-but adoption was constrained by delivery inefficiencies and suboptimal immunogenicity in humans. Recent advances in plasmid engineering, linear and minicircle DNA platforms, and a more nuanced understanding of innate immune modulation have reignited interest among developers, funders, and clinical investigators.

Consequently, technology maturation is converging with pragmatic clinical strategy. Electroporation and nanoparticle-based carriers are demonstrating improved antigen expression and immune priming in trial settings, and intradermal and intramuscular administration routes are being optimized to balance safety with immunologic potency. On the regulatory front, clearer guidance on vector characterization and manufacturing controls is facilitating more predictable development pathways. Taken together, these dynamics are reshaping the risk calculus for both established biologics companies and nimble biotech entrants, creating an environment in which strategic partnerships, targeted investments in delivery technologies, and curated clinical programs are central to realizing the long-promised utility of DNA vaccines.

Transformative shifts in technologies, clinical strategies, and stakeholder behavior that are accelerating DNA vaccine viability and strategic collaboration

The DNA vaccine landscape has experienced transformative shifts driven by three interlocking forces: technological refinement, clinical validation trends, and evolving stakeholder expectations. Advances in molecular scaffolding and vector design have expanded the repertoire of antigen constructs that can be reliably expressed in vivo, and the emergence of linear DNA and minicircle platforms is offering developers alternative trade-offs in expression efficiency and manufacturing simplicity. In parallel, improvements in delivery modalities such as electroporation and lipid- or polymer-based nanoparticles are materially reducing prior barriers to robust immune activation.

Clinical development strategies have also shifted toward combination approaches that pair DNA vaccines with adjuvants, heterologous prime-boost regimens, or checkpoint modulators in oncology. As a result, trial designs are increasingly adaptive and biomarker-driven, with a heavier emphasis on correlates of protection and immune durability. Moreover, the competitive landscape is adapting: long-term players are recalibrating portfolios to incorporate DNA vaccines where they complement existing modalities, while smaller innovators are focusing on niche indications or platform differentiation. These shifts collectively push the field toward pragmatic collaboration, targeted regulatory engagement, and selective capital deployment that prioritize demonstrable clinical value and manufacturable delivery solutions.

How evolving tariff dynamics and trade policy adjustments in 2025 are reshaping supply-chain strategies, procurement priorities, and manufacturing localization decisions

The cumulative impact of tariff changes and trade policy adjustments in 2025 has introduced additional complexity into global supply chains that underpin DNA vaccine development and production. Raw materials critical to plasmid and linear DNA production-specialized enzymes, chromatography resins, single-use bioprocess components, and reagent-grade consumables-are sensitive to cross-border cost fluctuations. Where tariffs have increased input prices or created greater procurement uncertainty, sponsors and contract development and manufacturing organizations have responded by reassessing sourcing strategies, extending inventory buffers, and pursuing localized supplier relationships to stabilize lead times.

These adjustments have practical downstream effects on program timelines and contracting practices. Developers are prioritizing dual-sourcing strategies, qualifying domestic manufacturing partners where feasible, and incorporating tariff contingencies into procurement contracts and milestone planning. Regulatory engagement has become more prominent as companies navigate import documentation, classification disputes, and compliance with evolving trade policies. At the same time, the trade environment has prompted more deliberate capital allocation toward regional manufacturing capabilities and supply-chain resilience initiatives, particularly for entities that view long-term commercial supply as a strategic differentiator rather than a short-term cost issue.

Key segmentation insights illuminating how application focus, platform choice, delivery modality, clinical stage, and end-user dynamics inform program strategy and commercialization planning

Segmentation-driven insights reveal distinct development pathways and commercial considerations across applications, technology platforms, delivery methods, administration routes, development stages, and end users. On the application axis, programs targeting infectious diseases-subdivided into bacterial infections, parasitic diseases, and viral infections-tend to emphasize rapid immune induction, cold-chain resilience, and scalability, while oncology programs focusing on hematological malignancies and solid tumors prioritize antigen specificity, combination immunotherapy strategies, and tumor microenvironment modulation. Platform selection-whether linear DNA, minicircle DNA, or plasmid DNA-shapes manufacturing complexity, payload capacity, and perceptions of genomic safety, influencing both regulatory dialogue and partner selection.

Delivery modalities exert a decisive influence on clinical strategy and patient experience. Electroporation has proven effective for enhancing transfection rates and is commonly paired with intramuscular or intradermal administration to maximize antigen expression, while gene gun approaches and nanoparticle delivery are being optimized to improve tolerability and enable mucosal routes such as intranasal delivery. Needle injection remains a pragmatic option in many clinical settings. Development stage segmentation, which spans preclinical to clinical phases I through III and commercial readiness, dictates different evidence requirements, investment profiles, and partnership models. Finally, the end-user landscape-comprising clinics, hospitals, and research institutions-drives considerations around ease of administration, on-site infrastructure needs, and training requirements, factors that are particularly salient when planning rollouts or pilot implementation studies.

Actionable regional insights that explain how regulatory, manufacturing, and healthcare system differences across the Americas, Europe Middle East & Africa, and Asia-Pacific direct program strategies

Regional perspectives shape strategic priorities for developers and investors across markets with differing regulatory frameworks, healthcare infrastructure, and manufacturing capacity. In the Americas, strong capital markets and an innovation-oriented regulatory environment encourage early-stage trials and public-private partnerships, while concentrated manufacturing clusters support rapid scale-up capabilities and vertically integrated supply chains. Conversely, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts coexist with varied access pathways and procurement mechanisms, prompting sponsors to adopt flexible clinical development plans and payer engagement strategies that reflect local reimbursement realities.

The Asia-Pacific region is characterized by dense manufacturing infrastructure, growing biotech ecosystems, and high-priority public health agendas that favor expedited adoption for vaccines demonstrating clear benefit. These regional attributes influence decisions about clinical trial localization, licensing strategies, and manufacturing siting. As a result, stakeholders are increasingly adopting regionally tailored approaches that align trial designs, regulatory submissions, and market access plans with local norms while preserving global program coherence. Transitioning smoothly across regions requires early cross-jurisdictional regulatory planning and strategic partnerships that can bridge technical, logistical, and policy gaps.

Critical company-level insights describing how platform innovators, clinical biotechs, large pharma partners, and CDMOs are aligning capabilities to accelerate DNA vaccine progress

The competitive and collaborative makeup of companies active in the DNA vaccine space spans specialist platform developers, clinical-stage biotechs, large pharmaceutical partners, and contract manufacturing organizations. Platform developers are differentiating through molecular design, proprietary delivery adjuncts, or manufacturing process innovations intended to reduce cost of goods and improve expression efficiency. Clinical-stage biotechs often focus on narrowly defined indications where a differentiated immunologic profile or compendium of biomarkers can accelerate proof-of-concept, while larger pharmaceutical firms tend to pursue strategic alliances or licensing arrangements to complement existing vaccine portfolios and distribution capabilities.

Contract development and manufacturing organizations play a pivotal role by offering scale, regulatory experience, and process optimization services that de-risk late-stage programs. Academic institutions and translational research centers also contribute through early-stage validation, platform refinement, and investigator-initiated trials. Across these organizational types, successful players balance technical depth with commercial pragmatism, invest in delivery and administration innovations, and cultivate regulatory engagement to smooth path-to-market barriers. Strategic collaborations that bring together complementary capabilities-such as combining a novel platform with an experienced clinical development partner and a CDMO capable of GMP supply-are increasingly the dominant route to de-risked advancement and broader clinical adoption.

Actionable recommendations for industry leaders to prioritize delivery innovation, supply-chain resilience, regulatory strategy, collaborative partnerships, and tailored commercialization playbooks

Industry leaders can adopt a set of pragmatic, high-impact actions to accelerate development and commercial readiness while mitigating risk. First, prioritize investment in delivery technologies and administration pathways that demonstrate reproducible improvements in antigen expression and patient tolerability, aligning these investments with target indication characteristics and end-user needs. Second, strengthen supply-chain resilience by qualifying multiple suppliers, exploring regional manufacturing partnerships, and embedding tariff and trade contingencies into procurement strategies to avoid program interruptions and protect timelines.

Third, pursue modular regulatory engagement and adaptive clinical designs that emphasize biomarker-driven endpoints and immune correlates, thereby reducing uncertainty and enabling faster go/no-go decisions. Fourth, cultivate cross-sector collaborations that pair molecular platform expertise with clinical development capability and scalable manufacturing to create end-to-end value chains. Finally, develop tailored commercialization playbooks that reflect regional regulatory norms, reimbursement pathways, and infrastructure constraints, and invest in training and administration support to ensure smooth deployment in clinics and hospitals. Together these actions create a defensible pathway from proof-of-concept through sustainable market access.

Research methodology describing the integrated approach of literature synthesis, regulatory review, expert consultations, and supply-chain analysis that underpins the findings

The research underlying this executive-level analysis combined a structured review of peer-reviewed literature, clinical trial registries, regulatory guidance documents, and publicly available technical reports with targeted expert consultations. Scientific and clinical inputs were triangulated to ensure consistency across preclinical validation, delivery modality performance, and clinical development patterns. Trade and policy impacts were assessed through analysis of recent tariff schedules, public trade notices, and supply-chain disruption case studies, with attention to how procurement and manufacturing decisions are adapting in real time.

Qualitative interviews with developers, contract manufacturers, clinical investigators, and regulatory advisors provided context on operational bottlenecks, technology adoption drivers, and preferred partnership archetypes. Throughout the study, findings were cross-checked for technical accuracy and relevance, and conclusions emphasized actionable implications over speculative forecasting. The methodological approach prioritized transparency, reproducibility, and the integration of technical, clinical, and commercial perspectives to produce a synthesis that supports strategic decision-making across stakeholders engaged in the DNA vaccine ecosystem.

Conclusion synthesizing technological progress, operational imperatives, and regional considerations that collectively define the path to DNA vaccine impact

In conclusion, DNA vaccines are transitioning from a primarily theoretical promise to a pragmatic element of contemporary immunotherapy and prophylactic strategies. Advances in platform engineering, coupled with meaningful improvements in delivery methods and administration practices, are expanding the set of indications where DNA vaccines can be competitively positioned. At the same time, external factors such as trade policy dynamics and diverse regional environments require deliberate planning around manufacturing, sourcing, and market-entry strategies.

For stakeholders, success depends on aligning scientific differentiation with operational excellence and regulatory foresight. Those who invest early in delivery optimization, supply-chain resilience, and collaborative partnership models will be positioned to convert technical promise into clinical impact and, ultimately, sustainable adoption. The pathway forward emphasizes targeted, evidence-driven development programs that are regionally informed and operationally pragmatic, enabling DNA vaccines to play a meaningful role in both infectious disease control and oncology care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA Vaccine Market, by Technology Platform

  • 8.1. Linear DNA
  • 8.2. Minicircle DNA
  • 8.3. Plasmid DNA

9. DNA Vaccine Market, by Delivery Method

  • 9.1. Electroporation
  • 9.2. Gene Gun
  • 9.3. Nanoparticle Delivery
  • 9.4. Needle Injection

10. DNA Vaccine Market, by Administration Route

  • 10.1. Intradermal
  • 10.2. Intramuscular
  • 10.3. Intranasal
  • 10.4. Subcutaneous

11. DNA Vaccine Market, by Development Stage

  • 11.1. Clinical Phase I
  • 11.2. Clinical Phase II
  • 11.3. Clinical Phase III
  • 11.4. Commercial
  • 11.5. Preclinical

12. DNA Vaccine Market, by Application

  • 12.1. Infectious Diseases
    • 12.1.1. Bacterial Infections
    • 12.1.2. Parasitic Diseases
    • 12.1.3. Viral Infections
  • 12.2. Oncology
    • 12.2.1. Hematological Malignancies
    • 12.2.2. Solid Tumors

13. DNA Vaccine Market, by End User

  • 13.1. Clinics
  • 13.2. Hospitals
  • 13.3. Research Institutions

14. DNA Vaccine Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. DNA Vaccine Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. DNA Vaccine Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States DNA Vaccine Market

18. China DNA Vaccine Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Aura Health
  • 19.6. Breethe
  • 19.7. Buddhify
  • 19.8. Calm
  • 19.9. Chopra Center
  • 19.10. Gaia
  • 19.11. Glo
  • 19.12. Headspace
  • 19.13. Inner Explorer
  • 19.14. Inscape
  • 19.15. Insight Network
  • 19.16. Inward
  • 19.17. MEDITOPIA
  • 19.18. Mindfulness Everywhere
  • 19.19. MOBIO INTERACTIVE
  • 19.20. Muse
  • 19.21. Omvana
  • 19.22. Pacifica
  • 19.23. Sattva
  • 19.24. Simple Habit
  • 19.25. Smiling Mind
  • 19.26. WAKING UP

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DNA VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DNA VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DNA VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DNA VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DNA VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DNA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DNA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DNA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS DNA VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL DNA VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GCC DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 173. GCC DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 174. GCC DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. GCC DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 178. GCC DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. G7 DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 200. G7 DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 201. G7 DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 203. G7 DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. G7 DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 205. G7 DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. G7 DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. NATO DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 209. NATO DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 210. NATO DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. NATO DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 214. NATO DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. NATO DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES DNA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA DNA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA DNA VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)